Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis [1] [2] [3].
In Vivo, Anti-Mouse CD47/IAP Antibody (MIAP301) (400 μg, i.p., single dose, 24 hours after the wound) significantly inhibits mucosal wound healing in male C57Bl/6J mice with a biopsy-based mucosal wound model[1]. Anti-Mouse CD47/IAP Antibody (MIAP301) (100 μg, intratumorally injection, once every three days, until the end of the study) significantly inhibits tumor growth and increases immune cell infiltration in the tumor microenvironment combined with Nexturastat A in female C57BL/6 mice bearing SM1 or B16F10 tumors[2]. Anti-Mouse CD47/IAP Antibody (MIAP301) (2.5 mg/kg, i.v., single dose, 1 or 8 hours after cecal ligation and puncture (CLP) surgery) significantly reduces the number of bacteria in blood and organs and improves survival rates in Balb/c or C57/BL6 mice with a Klebsiella pneumonia-induced sepsis model[3].
In Vitro, Anti-Mouse CD47/IAP Antibody (MIAP301) (10 μg/mL, 24 h) significantly inhibits epithelial cell migration and wound closure[1]. Anti-Mouse CD47/IAP Antibody (MIAP301) (0-4 h) inhibits the β1 integrin-FAK-SRc-p130Cas signaling pathway and reduces the level of p-SrcY 416, p-FAKY 397, p-FAKY Y861, p-p130Cas Y410 and β1 integrin[1]. Anti-Mouse CD47/IAP Antibody (MIAP301) (0-100 μg/mL, 1 h) effectively blocks CD47 and saturates its epitope in SM1 cells[2]. Anti-Mouse CD47/IAP Antibody (MIAP301) (25 μg/mL, 2-4 h) significantly enhances the phagocytic activity of macrophages towards SM1 cells[2]. Anti-Mouse CD47/IAP Antibody (MIAP301) (8 h) significantly restores the phagocytic ability of myeloid cells towards Escherichia coli[3].
References:
[1]. Reed M, et al. Epithelial CD47 is critical for mucosal repair in the murine intestine in vivo. Nat Commun. 2019 Nov 1;10(1):5004.
[2]. Gracia-Hernandez M, et al. Targeting HDAC6 improves anti-CD47 immunotherapy. J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.
[3]. Feng Z, et al. CD47-amyloid-β-CD74 signaling triggers adaptive immunosuppression in sepsis. EMBO Rep. 2025 May;26(10):2683-2714.
In Vivo, Anti-Mouse CD47/IAP Antibody (MIAP301) (400 μg, i.p., single dose, 24 hours after the wound) significantly inhibits mucosal wound healing in male C57Bl/6J mice with a biopsy-based mucosal wound model[1]. Anti-Mouse CD47/IAP Antibody (MIAP301) (100 μg, intratumorally injection, once every three days, until the end of the study) significantly inhibits tumor growth and increases immune cell infiltration in the tumor microenvironment combined with Nexturastat A in female C57BL/6 mice bearing SM1 or B16F10 tumors[2]. Anti-Mouse CD47/IAP Antibody (MIAP301) (2.5 mg/kg, i.v., single dose, 1 or 8 hours after cecal ligation and puncture (CLP) surgery) significantly reduces the number of bacteria in blood and organs and improves survival rates in Balb/c or C57/BL6 mice with a Klebsiella pneumonia-induced sepsis model[3].
In Vitro, Anti-Mouse CD47/IAP Antibody (MIAP301) (10 μg/mL, 24 h) significantly inhibits epithelial cell migration and wound closure[1]. Anti-Mouse CD47/IAP Antibody (MIAP301) (0-4 h) inhibits the β1 integrin-FAK-SRc-p130Cas signaling pathway and reduces the level of p-SrcY 416, p-FAKY 397, p-FAKY Y861, p-p130Cas Y410 and β1 integrin[1]. Anti-Mouse CD47/IAP Antibody (MIAP301) (0-100 μg/mL, 1 h) effectively blocks CD47 and saturates its epitope in SM1 cells[2]. Anti-Mouse CD47/IAP Antibody (MIAP301) (25 μg/mL, 2-4 h) significantly enhances the phagocytic activity of macrophages towards SM1 cells[2]. Anti-Mouse CD47/IAP Antibody (MIAP301) (8 h) significantly restores the phagocytic ability of myeloid cells towards Escherichia coli[3].
References:
[1]. Reed M, et al. Epithelial CD47 is critical for mucosal repair in the murine intestine in vivo. Nat Commun. 2019 Nov 1;10(1):5004.
[2]. Gracia-Hernandez M, et al. Targeting HDAC6 improves anti-CD47 immunotherapy. J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.
[3]. Feng Z, et al. CD47-amyloid-β-CD74 signaling triggers adaptive immunosuppression in sepsis. EMBO Rep. 2025 May;26(10):2683-2714.